Akèy › Myelom Miltip › New York
Etid klinik pou Myelom Miltip nan New York
75 etid pou Myelom Miltip ap chèche patisipan nan sit nan New York.
Vil nan New York
- New York City60 etid
- Queens20 etid
- New Rochelle14 etid
- Greenburgh13 etid
- Staten Island13 etid
- Buffalo10 etid
- Rochester8 etid
- The Bronx5 etid
- Albany4 etid
Tèks ofisyèl etid la (Anglè)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- ak 1 plis
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06679829A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Albany
- Research Site, New York
- Research Site, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05652335A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Hematology-Oncology Associates of CNY, East Syracuse
- Northwell Health Cancer Institute, Lake Success
- NYU Langone Hospital Long Island, Mineola
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mount Sinai Brooklyn, Brooklyn
- NYU Winthrop, Mineola
- Mount Sinai Chelsea, New York
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Icahn School of Medicine at Mt. Sinai, New York
- University of Rochester Medical Center, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06500884A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Roswell Park Cancer Institute, Buffalo
- Mount Sinai Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- ak 1 plis
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mount Sinai Medical Center, New York
- University of Rochester Medical Center, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04634552A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- MSK Commack, Commack
- MSK Westchester, Harrison
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05623020A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- New York Oncology Hematology, Albany
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health Manhattan, New York
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07393282A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07073547A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Memorial Sloan Kettering, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07336472A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Tisch Cancer Institute at Mount Sinai, New York
- Memorial Sloan-Kettering Cancer Center, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Northwell Health Monter Cancer Center, Lake Success
- Northern Westchester Hospital, Mount Kisco
- Cohen Children's Medical Center, New Hyde Park
- ak 4 plis
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Icahn School of Medicine at Mount Sinai /ID# 277844, New York
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
- Weill Cornell Medicine Myeloma Center /ID# 278216, New York
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- David H. Koch Center for Cancer Care, New York
- Montefiore Medical Center PRIME, The Bronx
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Mount Sinai, The Tisch Cancer Instutute, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04879043Collection of Tissue Samples for Cancer Research
- Roswell Park Cancer Institute, Buffalo
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Weill Cornell Medical College, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06615479Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Mount Sinai Hospital, New York
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06976476A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06953960Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
- Icahn School of Medicine at Mount Sinai, New York
Ap rekriteFaz 2
Laj 70 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06827860Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Roswell Park Cancer Institute, Buffalo
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- New York Oncology Hematology, Albany
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06980480Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06375044A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- MSK Commack, Commack
- MSK Westchester, Harrison
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05020236MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- University of Rochester, Rochester
- State University of New York Upstate Medical University, Syracuse
- Upstate Cancer Center at Verona, Verona
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06106945Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
- Roswell Park Cancer Institute, Buffalo
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06627751A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Memorial Sloan-Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Roswell Park Comprehensive Cancer Center, Buffalo
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06292780A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07105059AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Buffalo
- Research Site, New York
- Research Site, Stony Brook
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Albany
- Research Site, New Hyde Park
- Research Site, New York
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Roswell Park Comprehensive Cancer Center, Buffalo
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT06622005A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Perlmutter Cancer Center at NYU Langone Hospital, Brooklyn
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013Delayed Toxicities Post-CAR-T
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT07665307Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.